Research May 25, 2021 • 2 Min
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Research November 1, 2018 • 5 Min
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Research June 27, 2017 • 2 Min
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Research March 10, 2017 • 2 Min
Maintenance Chemotherapy for Stable Metastatic Pancreatic Cancer
A clinical trial tests the diabetes drug metformin and transplant rejection preventative rapamycin to act as maintenance chemotherapy for pancreatic cancer.
Research July 26, 2016 • 2 Min
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.